The article presents a case study of a 50-year-old male who was diagnosed with hereditary haemorrhagic telangiectasia (HHT) and was treated by using low dose intravenous bevacizumab.
Publication
British Journal of Haematology, 2011, Vol 152, Issue 4, p365